Cargando…
Relugolix: A Review in Advanced Prostate Cancer
Relugolix (Orgovyx(®)), an orally active nonpeptide gonadotropin-releasing hormone (GnRH) receptor antagonist that provides rapid testosterone suppression, is indicated in the USA for the treatment of advanced prostate cancer and in the EU for advanced hormone-sensitive prostate cancer. In the pivot...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198864/ https://www.ncbi.nlm.nih.gov/pubmed/36652173 http://dx.doi.org/10.1007/s11523-022-00944-4 |